<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The molecular basis for the development of appendiceal <z:e sem="disease" ids="C1334811" disease_type="Neoplastic Process" abbrv="">mucinous tumours</z:e>, which can be a cause of <z:mpath ids='MPATH_303'>pseudomyxoma peritonei</z:mpath>, remains largely unknown </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Thirty-five appendiceal mucinous <z:hpo ids='HP_0002664'>neoplasms</z:hpo> were analysed for GNAS and KRAS mutations </plain></SENT>
<SENT sid="2" pm="."><plain>A functional analysis of mutant GNAS was performed using a <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cell line </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: A mutational analysis identified activating GNAS mutations in 16 of 32 low-grade appendiceal mucinous <z:hpo ids='HP_0002664'>neoplasms</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LAMNs</z:e>) but in none of three mucinous <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> (MACs) </plain></SENT>
<SENT sid="4" pm="."><plain>KRAS mutations were found in 30 LAMNs and in <z:hpo ids='HP_0000001'>all</z:hpo> MACs </plain></SENT>
<SENT sid="5" pm="."><plain>We additionally analysed a total of 186 extra-appendiceal <z:e sem="disease" ids="C1334811" disease_type="Neoplastic Process" abbrv="">mucinous tumours</z:e> and found that GNAS mutations were highly prevalent in intraductal papillary <z:e sem="disease" ids="C1334811" disease_type="Neoplastic Process" abbrv="">mucinous tumours</z:e> of the pancreas (88%) but were rare or absent in <z:e sem="disease" ids="C1334811" disease_type="Neoplastic Process" abbrv="">mucinous tumours</z:e> of the colorectum, ovary, lung and breast (0-9%) </plain></SENT>
<SENT sid="6" pm="."><plain>The prevalence of KRAS mutations was quite variable among the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>The introduction of the mutant GNAS into a <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cell line markedly induced MUC2 and MUC5AC expression, but did not promote cell growth either in vitro or in vivo </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: Activating GNAS mutations are a frequent and characteristic genetic abnormality of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LAMN</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Mutant GNAS might play a direct role in the prominent mucin production that is a hallmark of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LAMN</z:e> </plain></SENT>
</text></document>